Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ABT is in the long-term up 85% in 3 years.
Description: Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company?s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification,
|Shares Outstanding||EPS||0.94||EPS Growth - 4 Quarters||1349.62%||EPS Growth - Q/Q||238.84%|
|EPS Growth - Y/Y||-44.39%||Sales Growth - 4 Quarters||-18.92%||Sales Growth - Q/Q||-7.43%||P/E||51.29|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||9.75%||ROE||19.21%||ROI||12.44%|
|Current Ratio||2.17||Quick Ratio||1.89||Long Term Debt/Equity||0.55||Debt Ratio||0.42|
|Gross Margin||55.74%||Operating Margin||13.95%||Net Profit Margin||20.6%||Dividend Payout Ratio||-32.44%|
|Cash From Financing Activities||-550 M||Cash From Investing Activities||-205 M||Cash From Operating Activities||2 M||Gross Profit||2.95 B|
|Net Profit||784 M||Operating Profit||729 M||Total Assets||43.1 B||Total Current Assets||19.99 B|
|Total Current Liabilities||9.21 B||Total Debt||8.46 B||Total Liabilities||21.22 B||Total Revenue||5.17 B|
|High 52 week||79.73||Low 52 week||53.74||Last close||75.97||Last change||-0.82%|
|RSI||36.28||Average true range||1.51||Beta||0.56||Volume||3.81 M|
|Simple moving average 20 days||-1.58%||Simple moving average 50 days||-2.29%||Simple moving average 200 days||14.05%|
|Performance Week||-0.63%||Performance Month||4.24%||Performance Quart||1.37%||Performance Half||29.53%|
|Performance Year||36.11%||Performance Year-to-date||22.22%||Volatility daily||1.12%||Volatility weekly||2.5%|
|Volatility monthly||5.12%||Volatility yearly||17.75%||Relative Volume||228.71%||Average Volume||5.53 M|
|New High||New Low|
2019-06-25 10:32:02 | Abbvie Decides to Acquire Allergan
2019-06-25 10:14:02 | AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20
2019-06-25 09:10:40 | Allergan Is a $63 Billion Botox Job for AbbVie
2019-06-25 00:00:25 | Smith & Nephew directors discussed US listing to boost CEO pay
2019-06-24 09:00:00 | Nutrition Is the Missing Ingredient in Home Health Today, New Study Shows
2019-06-19 09:00:00 | Abbott Hosts Conference Call for Second-Quarter Earnings
2019-06-19 08:00:00 | Is Abbott Laboratories a Buy?
2019-06-19 07:34:09 | How Do Rate Cuts Impact Healthcare Stocks?
2019-06-18 17:50:09 | Abbott ABT Outpaces Stock Market Gains: What You Should Know
2019-06-17 07:40:11 | Abbott ABT Hits New 52-Week High on Solid Growth Drivers
2019-06-14 10:45:00 | Abbott Declares 382?? Consecutive Quarterly Dividend
2019-06-13 09:00:01 | Abbott ABT Moves to Buy: Rationale Behind the Upgrade
2019-06-13 09:00:00 | New Survey Shows Millennials Can Help Avoid Blood Shortages
2019-06-12 08:28:15 | Traders Look to Buy Global Health Care Stocks
2019-06-10 17:45:09 | Abbott ABT Outpaces Stock Market Gains: What You Should Know
2019-06-10 16:40:40 | Here’s What Hedge Funds Think About Abbott Laboratories ABT
2019-06-10 09:38:01 | The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
2019-06-09 07:00:00 | Where Will Abbott Laboratories Be in 10 Years?
2019-06-08 13:00:01 | Abbott device helps in cutting blood sugar in type 2 diabetics - study
2019-06-07 13:09:05 | Top Research Reports for Mastercard, Disney & Abbott
2019-06-06 09:30:01 | Is Abbott Laboratories ABT Outperforming Other Medical Stocks This Year?
2019-06-04 17:45:09 | Abbott ABT Gains But Lags Market: What You Should Know
2019-06-04 11:47:03 | Abbott ABT Grows on EPD Amid Rhythm Management Challenges
2019-06-04 08:01:32 | See what the IHS Markit Score report has to say about Gannett Co Inc.
2019-06-03 14:15:54 | Did Abbott Laboratories NYSE:ABT Use Debt To Deliver Its ROE Of 8.3%?
2019-06-01 21:08:08 | Here is the 18th Most Popular Stock Among Hedge Funds
2019-05-29 17:50:09 | Abbott ABT Stock Moves -0.05%: What You Should Know
2019-05-29 09:31:49 | The Top Health Care Companies in the World
2019-05-24 13:44:27 | The highest-paid CEOs by state
2019-05-24 12:21:43 | One sector is making a comeback amid market volatility
2019-05-23 17:45:09 | Abbott ABT Dips More Than Broader Markets: What You Should Know
2019-05-22 11:27:00 | 3 Dividend Aristocrats to Buy and Hold Forever
2019-05-18 10:25:49 | Should Abbott Laboratories NYSE:ABT Be Part Of Your Dividend Portfolio?
2019-05-17 09:30:01 | Why Is Abbott ABT Up 3.6% Since Last Earnings Report?
2019-05-15 05:34:09 | Bull of the Day: Penumbra PEN
2019-05-13 10:37:02 | Abbott Rides on Strong CGM, Poor Rhythm Management Ails
2019-05-10 09:00:01 | Abbott ABT Upgraded to Buy: What Does It Mean for the Stock?
2019-05-09 17:56:00 | Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman
2019-05-08 14:03:06 | Top Stock Reports for Verizon, Abbott & Illinois Tool Works
2019-05-08 11:35:03 | Haemonetics HAE Q4 Earnings Top Mark, Operating Margin Up